KR20220131246A - 항-trem2 항체 및 이의 사용 방법 - Google Patents

항-trem2 항체 및 이의 사용 방법 Download PDF

Info

Publication number
KR20220131246A
KR20220131246A KR1020227025637A KR20227025637A KR20220131246A KR 20220131246 A KR20220131246 A KR 20220131246A KR 1020227025637 A KR1020227025637 A KR 1020227025637A KR 20227025637 A KR20227025637 A KR 20227025637A KR 20220131246 A KR20220131246 A KR 20220131246A
Authority
KR
South Korea
Prior art keywords
seq
antibody
amino acid
acid sequence
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227025637A
Other languages
English (en)
Korean (ko)
Inventor
마크 에스. 데니스
젠유 구
미할리스 에스. 카리올리스
카헐 에스. 마혼
캐스린 엠. 먼로
조슈아 아이. 박
레이첼 프로로크
아담 피. 실버맨
베티나 반 렝게리히
Original Assignee
데날리 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데날리 테라퓨틱스 인크. filed Critical 데날리 테라퓨틱스 인크.
Priority claimed from PCT/US2021/013200 external-priority patent/WO2021146256A1/en
Publication of KR20220131246A publication Critical patent/KR20220131246A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020227025637A 2020-01-13 2021-01-13 항-trem2 항체 및 이의 사용 방법 Pending KR20220131246A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062960663P 2020-01-13 2020-01-13
US62/960,663 2020-01-13
US202063070728P 2020-08-26 2020-08-26
US63/070,728 2020-08-26
US202063091717P 2020-10-14 2020-10-14
US63/091,717 2020-10-14
PCT/US2021/013200 WO2021146256A1 (en) 2020-01-13 2021-01-13 Anti-trem2 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20220131246A true KR20220131246A (ko) 2022-09-27

Family

ID=76760857

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227025637A Pending KR20220131246A (ko) 2020-01-13 2021-01-13 항-trem2 항체 및 이의 사용 방법

Country Status (13)

Country Link
US (2) US11124567B2 (https=)
EP (1) EP4090682A1 (https=)
JP (1) JP2023512450A (https=)
KR (1) KR20220131246A (https=)
CN (1) CN115279790A (https=)
AU (1) AU2021208482B2 (https=)
BR (1) BR112022013756A2 (https=)
CA (1) CA3166385A1 (https=)
CO (1) CO2022009744A2 (https=)
IL (1) IL294655A (https=)
MX (1) MX2022008582A (https=)
PE (1) PE20221465A1 (https=)
PH (1) PH12022551650A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024253424A1 (ko) * 2023-06-09 2024-12-12 재단법인대구경북과학기술원 인간 trem2 단백질에 특이적으로 결합하는 인간화 항체 및 이의 용도

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506055A (zh) 2017-02-17 2019-11-26 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
BR112021015656A2 (pt) 2019-02-20 2021-10-05 Denali Therapeutics Inc. Anticorpos anti-trem2 e métodos de uso dos mesmos
PH12022551598A1 (en) 2019-12-23 2023-11-20 Denali Therapeutics Inc Progranulin variants
JP7745557B2 (ja) * 2020-02-24 2025-09-29 アレクトル エルエルシー 抗ｔｒｅｍ２抗体の使用方法
EP4229192A1 (en) 2020-10-14 2023-08-23 Denali Therapeutics Inc. Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
WO2023192288A1 (en) * 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN117624360A (zh) * 2022-08-26 2024-03-01 南京融捷康生物科技有限公司 一种抗trem2的单域抗体及其用途
JP2025529287A (ja) 2022-09-06 2025-09-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト
CN116041481B (zh) * 2022-09-13 2024-01-19 北京湃德智健科技有限公司 一种用于检测trem2自身抗体的抗原多肽及其应用
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2024253420A1 (ko) * 2023-06-09 2024-12-12 재단법인대구경북과학기술원 인간 trem2 단백질에 특이적으로 결합하는 인간 항체 및 이의 용도
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2026062585A1 (en) * 2024-09-20 2026-03-26 Novartis Ag Methods of treatment using anti-trem2 antibodies
WO2026062582A1 (en) * 2024-09-20 2026-03-26 Novartis Ag Methods of treatment using anti-trem2 antibodies

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
TWI541021B (zh) 2009-03-05 2016-07-11 艾伯維有限公司 Ｉｌ－１７結合蛋白
BR112015027313A2 (pt) 2013-04-29 2017-09-26 Teva Pharmaceuticals Australia Pty Ltd anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado
WO2015033223A2 (en) 2013-09-03 2015-03-12 Novimmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
CN105218669A (zh) 2014-06-10 2016-01-06 河北翰林生物科技有限公司 制备抗人r47h-trem2突变体的人单克隆抗体的方法
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
CA2961950A1 (en) 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
US20190330335A1 (en) * 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
WO2017147509A1 (en) 2016-02-25 2017-08-31 Marco Colonna Compositions comprising trem2 and methods of use thereof
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CN109641961A (zh) 2016-07-22 2019-04-16 德国神经退行性疾病研究中心 Trem2切割调节剂及其用途
CA3048224A1 (en) 2016-12-23 2018-06-28 Bluefin Biomedicine, Inc. Anti-sez6l2 antibodies and antibody drug conjugates
EP3570883A2 (en) 2017-01-17 2019-11-27 Yeda Research and Development Co. Ltd Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
US10457717B2 (en) * 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
SG11201907422RA (en) * 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
CN110506055A (zh) * 2017-02-17 2019-11-26 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
BR112020001060A2 (pt) 2017-07-27 2020-07-14 Novartis Ag variantes de trem2 resistentes a shedase
DK3601358T5 (da) 2017-08-03 2024-09-02 Alector Llc Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
EP3665194A4 (en) * 2017-08-10 2021-07-07 Denali Therapeutics Inc. AFFINITY BASED METHODS OF USING TRANSFERRIN RECEPTOR BINDING PROTEINS
WO2019055841A1 (en) * 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
US20210186917A1 (en) 2017-10-17 2021-06-24 The Translational Genomics Research Institute Trem2 agonists for the stimulation of microglia and methods of identification
WO2019094608A1 (en) * 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
AU2018383709B2 (en) 2017-12-12 2025-09-11 Pionyr Immunotherapeutics, Inc. Anti-TREM2 antibodies and related methods
TW201934573A (zh) 2018-01-10 2019-09-01 美商戴納立製藥公司 轉鐵蛋白受體結合性多肽及其用途
WO2019246071A1 (en) 2018-06-18 2019-12-26 Denali Therapeutics Inc. Fusion proteins comprising progranulin
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
WO2020037150A2 (en) 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
JP2021534220A (ja) 2018-08-22 2021-12-09 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法
CA3111569A1 (en) 2018-09-11 2020-03-19 Washington University Anti-trem-2 agonist antibodies
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
KR102156165B1 (ko) 2018-10-29 2020-09-15 재단법인대구경북과학기술원 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
CA3120970A1 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
US12351629B2 (en) 2018-12-10 2025-07-08 Mor Research Applications Ltd. TREM2 antibodies and uses thereof
US20220025065A1 (en) 2018-12-10 2022-01-27 Denali Therapeutics Inc. Lysosomal storage disorder biomarkers and methods of use thereof
KR20210104079A (ko) 2018-12-11 2021-08-24 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 항-trem2 항체를 사용하는 방법
BR112021015656A2 (pt) * 2019-02-20 2021-10-05 Denali Therapeutics Inc. Anticorpos anti-trem2 e métodos de uso dos mesmos
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
CA3134538A1 (en) 2019-04-03 2020-10-08 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024253424A1 (ko) * 2023-06-09 2024-12-12 재단법인대구경북과학기술원 인간 trem2 단백질에 특이적으로 결합하는 인간화 항체 및 이의 용도

Also Published As

Publication number Publication date
CA3166385A1 (en) 2021-07-22
AU2021208482B2 (en) 2025-12-11
IL294655A (en) 2022-09-01
AU2021208482A1 (en) 2022-07-21
JP2023512450A (ja) 2023-03-27
PE20221465A1 (es) 2022-09-21
BR112022013756A2 (pt) 2022-10-11
CO2022009744A2 (es) 2022-07-19
EP4090682A1 (en) 2022-11-23
PH12022551650A1 (en) 2024-02-12
US11124567B2 (en) 2021-09-21
MX2022008582A (es) 2022-08-10
US20220177576A1 (en) 2022-06-09
CN115279790A (zh) 2022-11-01
US20210214438A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
US11124567B2 (en) Anti-TREM2 antibodies and methods of use thereof
US12240902B2 (en) Anti-TREM2 antibodies and methods of use thereof
TWI890727B (zh) 抗trem2 抗體及其使用方法
JP7403441B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
CN113453700B (zh) 拮抗剂
KR20240133705A (ko) 항-pilra 항체, 이의 용도, 및 관련 방법 및 시약
HK40082564A (en) Anti-trem2 antibodies and methods of use thereof
US20250215077A1 (en) Monovalent anti-trem2 binding molecules and methods of use thereof
EA049305B1 (ru) Антитела к trem2 и способы их применения
HK40063035A (en) Anti-trem2 antibodies and methods of use thereof
TW202515915A (zh) 抗ｐｉｌｒａ抗體、其用途以及相關方法及試劑

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902